NCT01238692 2023-03-24A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)Jewish General HospitalPhase 2 Completed42 enrolled
NCT01261247 2022-05-24Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaMayo ClinicPhase 2 Completed41 enrolled 8 charts
NCT00918333 2020-03-10Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaMayo ClinicPhase 1/2 Completed124 enrolled 10 charts
NCT01523834 2019-11-22FIL_PanAL10Fondazione Italiana Linfomi - ETSPhase 2 Completed35 enrolled 10 charts
NCT00962507 2013-02-15Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCity of Hope Medical CenterPhase 1 Completed11 enrolled